Skip to content

Author

Ehab A. M. El-Shoura

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Ivabradine alleviates the cisplatin-induced cardiotoxicity in rats through regulating the crosstalk between MLCP/PKG, MEK/ERK pathways and miRNA-34a levels.

BACKGROUND Ivabradine (IVA), a broad-spectrum inhibitor of HCN cation channels, is recognized for enhancing cardiac function in the treatment of cardiovascular diseases and may serve as a potential therapeutic agent for mitigating drug-induced cardiotoxicity. This study aimed to investigate the protective effect of IVA against cardiac damage induced by cisplatin (Cis) and to elucidate the underlying mechanisms. METHODS We investigated the impact of IVA (5 mg/kg, orally for 28 consecutive days) on Cisplatin-induced cardiac injury (7.5 mg/kg intraperitoneally on day 5) in rats. Biomarkers of oxidative stress and levels of inflammatory cytokines in cardiac tissue were assessed. H&E staining was employed to identify histopathological alterations in cardiac tissue. The molecular mechanisms of IVA in ameliorating cardiac injury were examined. RESULTS The results indicated that IVA enhanced cardiac tissue structure by suppressing the pathological alterations observed in H&E staining. IVA demonstrated antioxidant and anti-inflammatory properties through reducing malonaldehyde (MDA), NADPH oxidase, tumor necrosis factor-α (TNF-α), and interleukins (IL-1β and IL-6) levels, while elevating superoxide dismutase (SOD), IL-10, and eNOS levels. IVA diminished the expression of cAMP response element-binding protein (CREB), Extracellular signal-regulated kinase (ERK), Mitogen-activated protein kinase kinase (MEK), Protein Kinase C-epsilon (PKC epsilon), and microRNA-34a (miRNA-34a), while enhancing the expression of Protein Kinase G (PKG), Myosin Light Chain Phosphatase (MLCP), and Rapidly Accelerated Fibrosarcoma (Raf-1), as confirmed by western blotting and PCR results. Furthermore, its impact on cardiac tissue viability was supported by increased B-cell lymphoma 2 (Bcl2) levels and decreased caspase-3 staining in immunohistopathology. CONCLUSION IVA may significantly mitigate cardiac injury in Cis-induced cardiotoxicity through regulating multiple pathways and miRNA-34a levels.

N. Aldabaan, BaselA Abdel-Wahab, Ehab A. M. El-Shoura et al. · 0 citations
Open access Sep 2026

Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways

ABSTRACT Hepatotoxicity is one of the most crucial side effects of chemotherapy administration. Obeticholic acid (OCA) is a semisynthetic bile acid and farnesoid X receptor (FXR) agonist derived from chenodeoxycholic acid, with reported antioxidant and anti‐inflammatory effects in liver disorders. This study investigated the hepatoprotective effect of OCA against commonly used chemotherapy cisplatin (CP)‐induced hepatotoxicity in rats, as well as the modulatory effects of edaravone (EDA), a potent free radical scavenger, on its effects. Rats were divided into five groups: control (received vehicle), CP (7.5 mg/kg), EDA (30 mg/kg) + CP, OCA (30 mg/kg) + CP, and EDA + OCA + CP. The results of the present study demonstrated that both OCA and EDA significantly mitigated liver damage caused by CP, as evidenced by restoring liver enzymes and histological structure, reestablishment of oxidant/antioxidant status, suppression of inflammation, and attenuation of pro‐death signaling. The study highlights the role of key molecular pathways, including Keap1/Nrf2/HO‐1,HO‐1, TNF‐α/NF‐κB, and AKT/GSK‐3β, in the hepatoprotective mechanisms of OCA. Collectively, these findings suggest that OCA and EDA, particularly in combination, attenuate CP‐induced hepatotoxicity and are associated with coordinated modulation of oxidative stress, inflammatory signaling, and AKT/GSK‐3β‐associated pro‐survival/pro‐death pathways.

Fares E. M. Ali, Adel G. Bakr, Abdel-Gawad S. Shalkami et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.